secwatch.observer — SEC 8-K summary
======================================

Issuer:     INCYTE CORP (INCY)
CIK:        0000879169
Form:       8-K
Filed at:   2024-10-29T23:59:59+00:00
Accession:  0000879169-24-000169
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Incyte Q3 2024 revenues up 24% to $1.14B; Jakafi guidance raised
----------------------------------------------------------------

- Total revenues $1.138B (+24% YoY); Jakafi net revenue $741M (+16%); Opzelura $139M (+52%).
- GAAP diluted EPS $0.54 vs $0.76 YoY; Non-GAAP diluted EPS $1.07 vs $1.10.
- Jakafi 2024 guidance raised to $2.74-2.77B; Other Heme/Onco guidance reduced to $310-320M.
- FDA approved Niktimvo (axatilimab) for chronic GVHD; sNDA filed for ruxolitinib cream in pediatric AD.
- Phase 3 retifanlimab in SCAC and tafasitamab in FL met endpoints; sBLAs planned by end of 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/879169/000087916924000169/0000879169-24-000169-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/879169/000087916924000169/incy-20241029.htm
  HTML page:      https://secwatch.observer/filing/0000879169-24-000169

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer